
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Holdings Inc. is positioned for significant growth due to its strong commercial performance from WAKIX and an advancing pipeline of drug candidates, which are expected to initiate or report results from multiple registrational trials in the next 12 to 18 months. The company maintains a robust balance sheet that supports its internal research and development efforts as well as potential business development opportunities. Despite the setback of ZYN002 not meeting its primary endpoint, the consistent execution in business operations and the potential of its pipeline contribute to a positive outlook for the company's future growth in the neurology sector.
Bears say
The analysis of Harmony Biosciences Holdings Inc indicates a significant setback due to the inability of its drug candidate ZYN002 to meet the primary endpoint in the pivotal Phase 3 RECONNECT trial, primarily attributed to a higher-than-expected placebo response. This revelation raises concerns regarding the efficacy of their pipeline and the capability to deliver therapeutic benefits in a critical patient population with unmet medical needs. Furthermore, the challenges faced in this trial may impact investor confidence and future revenue expectations, thereby contributing to a negative outlook on the company's stock performance.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares